John Albert, MD
Rheumatology · Glendale, WINPI 1861428070
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $262,768 of the $369,274 with a category attached, or 71.2%. Amgen accounts for 85.8% of it on its own, with 36 other manufacturers making up the rest. Among rheumatology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,295 payments — averaging $285.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$317K
- Sobi, Inc$35K
- Boehringer Ingelheim$6K
- AstraZeneca$2K
- AbbVie$1K
- ANI Pharmaceuticals, Inc.$1K
- plus $6K from 31 others
Across 1 payment — averaging $309.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$309
What the payments were for
- Consulting fees$36,53510%
- Speaking & faculty fees$262,76871%
- Travel & lodging$44,73112%
- Food & beverage$24,8227%
- Education$4170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 638 | $316,961 |
| Sobi, Inc | 56 | $35,463 |
| Boehringer Ingelheim | 17 | $6,131 |
| AstraZeneca(2 entities) | 52 | $1,830 |
| AbbVie | 101 | $1,291 |
| ANI Pharmaceuticals, Inc. | 40 | $1,150 |
| UCB, Inc. | 63 | $1,021 |
| Novartis | 56 | $1,002 |
| Pfizer | 77 | $795 |
| Johnson & Johnson | 36 | $723 |
| Lilly USA, LLC | 31 | $528 |
| GSK | 38 | $463 |
| Mallinckrodt Hospital Products Inc. | 10 | $296 |
| E.r. Squibb & Sons, L.L.C. | 11 | $204 |
| Genentech USA, Inc. | 9 | $191 |
| Organon | 7 | $149 |
| Sanofi | 8 | $148 |
| Sandoz | 6 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $91 |
| Radius Health, Inc. | 4 | $85 |
| Ultragenyx Pharmaceutical Inc. | 4 | $85 |
| Celltrion USA Inc. | 2 | $69 |
| Ferring Pharmaceuticals Inc. | 3 | $66 |
| Aurinia Pharma U.S., Inc. | 4 | $65 |
| Fresenius Kabi USA, LLC | 3 | $64 |
| Hospira, Inc. | 3 | $60 |
| Collegium Pharmaceutical, Inc. | 3 | $44 |
| Pacira Therapeutics, Inc. | 1 | $28 |
| United Therapeutics Corporation | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Merck | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Bioventus LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$369,274 in reported general payments places this provider in the 95th percentile of 120 rheumatology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 104 | $848,895 |
| CortrophinCorticotropin | 12 | $720,913 |
| RinvoqUpadacitinib | 61 | $397,165 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 18 | $295,449 |
| Cosentyx Unoready PenSecukinumab | 14 | $202,644 |
| Enbrel SureclickEtanercept | 20 | $181,997 |
| Cimzia (2 Pack)Certolizumab Pegol | 22 | $142,329 |
| Humira PenAdalimumab | 17 | $119,211 |
| XeljanzTofacitinib Citrate | 26 | $118,404 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $102,879 |
| RasuvoMethotrexate/Pf | 24 | $13,974 |
| Hydroxychloroquine Sulfate | 243 | $12,790 |
| Febuxostat | 77 | $8,225 |
| MethotrexateMethotrexate Sodium | 350 | $6,237 |
| Azathioprine | 26 | $3,542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,291 | $397,16561 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,021 | $142,32922 claims |
| PfizerXeljanz | $795 | $118,40426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 rheumatology providers in Wisconsin.
Other rheumatology in Glendale
- Kurt OelkeGlendale$750K
- Arnold LimGlendale$8K
- Jonathan KushiGlendale$5K
- Katherine FinnGlendale$2K
- Farrukh PashaGlendale$1K
- Steven BergquistGlendale$722
- Juliana ShahGlendale$513
- Daniel MaloneBeaver Dam$505K
- Taraneh MehraniMenomonee Falls$176K
- Ekaterina SoforoSheboygan$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.